Across the EU and beyond, ACE-031, in its 1 milligram formulation , is gaining traction as a potential treatment for certain neurological conditions . Current studies in countries like the Federal Republic and France are investigating its efficacy on clinical results . Organizations throughout the region are closely monitoring the development of AC